CD274 and non-small cell lung carcinoma: In NSCLC patients, there was a correlation between PD-L1 expression and response to treatment, in which patients were stratified based on PD-L1 status on tumor-infiltrating immune cells and tumor cells and randomized to receive either atezolizumab or docetaxel (76).